F8 protein, human clinical trials
Counted the way a researcher would: F8 protein, human with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses F8 protein, human is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 24 Jan 1974 · Koate, Koate-Dvi · BLA 101130 (FDA, Purple Book)
- European Union
- 12 Aug 2013 · Voncento · EMEA/H/C/002493 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 4 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 1
Bayer (9) · Baxalta now part of Shire (8) · CSL Behring (1) · Nanjing Medical University (1)
Often tested with
Tested in the same studies.
Antihemophilic factor, human recombinant (9) · Vonicog alfa (1) · Lonoctocog alfa (1)
Related medicines
As reviewed, each with the page that says it.
- Antihemophilic factor, human recombinant is a recombinant medicine of it, counted here with related medicines source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
F8 protein, human is the comparator. A study of two new drugs counts under both.
- 1NXT007 · Hoffmann-La Roche · next primary completion Sep 2027
Studies
Open first, then newest update. How each study uses F8 protein, human is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT02932618Written as Antihemophilic Factor (Recombinant)How we know
- Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedPhase 2/3Baxalta now part of ShireNCT00157105Written as Antihemophilic factor, recombinant, manufactured protein-freeHow we know
- Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedPhase 2/3Baxalta now part of ShireNCT00157053Written as Antihemophilic factor, recombinant, manufactured protein-freeHow we know
- Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00289536Written as Antihemophilic factor, recombinant, manufactured protein-freeHow we know
- Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00243386Written as Antihemophilic factor, recombinant, manufactured protein-freeHow we know
- Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00916032Written as Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]How we know
- China ADVATE PTP StudyCompletedPhase 4Baxalta now part of ShireNCT02170402Written as Octocog alfa (recombinant human coagulation factor VIII)How we know
- Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia ACompletedPhase 2/3Baxalta now part of ShireNCT00157040Written as Antihemophilic factor, recombinant, manufactured protein-freeHow we know
- Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia ACompletedPhase 3BayerNCT01029340Written as Recombinant Factor VIII (BAY81-8973)How we know
- A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia ACompletedPhase 3BayerNCT01233258Written as rFVIII (BAY81-8973) on demandHow we know
- An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia ACompletedPhase 2/3CSL BehringNCT01486927Written as Octocog alfaHow we know
- Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and AdvateCompletedPhase 1BayerNCT02483208Written as BAY81-8973How we know
- Prophylaxis Versus on Demand Treatment for Children With Hemophilia ACompletedPhase 4BayerNCT01810666Written as Recombinant Factor VIII (Kogenate FS, BAY14-2222)How we know
- Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia ATerminatedPhase 4BayerNCT00621673Written as Kogenate (BAY 14-2222)How we know
- Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic TreatmentCompletedPhase 3BayerNCT00623480Written as Recombinant Factor VIII (Kogenate FS, BAY14-2222)How we know
- BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)CompletedPhase 4BayerNCT00586521Written as Kogenate (BAY14-2222)How we know
- Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia AStatus unknownNot applicableNanjing Medical UniversityNCT02280265Written as Recombinant Human Coagulation Factor VIII for injectionHow we know
- Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222CompletedPhase 1BayerNCT01653639Written as Recombinant Factor VIII (Kogenate FS, BAY14-2222)How we know
- BAY14-2222 Continuous Infusion in SurgeriesCompletedPhase 3BayerNCT00606060Written as Kogenate (BAY14-2222)How we know
Given beside what is tested · 4 — F8 protein, human is usual care or a partner of the new treatment
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ACompletedPhase 1SanofiNCT05042440Written as Octocog alfaHow we know
- A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)CompletedPhase 3Baxalta now part of ShireNCT03879135Written as rFVIIIHow we know
- rVWF IN PROPHYLAXISCompletedPhase 3TakedaNCT02973087Written as Antihemophilic Factor (Recombinant)How we know
- BAX 826 Dose-Escalation Safety StudyCompletedPhase 1Baxalta now part of ShireNCT02716194Written as Octocog alfaHow we know
As the comparator · 4 — what is tested is compared with F8 protein, human
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ARecruitingPhase 3Hoffmann-La RocheNCT07416526Written as Human Coagulation Factor VIIIHow we know
- Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia ACompletedPhase 4Baxalta now part of ShireNCT00666406Written as Recombinant Factor VIII (rAHF)How we know
- Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia ACompletedPhase 2OctapharmaNCT00989196Written as Kogenate FSHow we know
- Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980CompletedPhase 1BayerNCT00629837Written as Recombinant Factor VIII (Kogenate FS, BAY14-2222)How we know
Codes
What other systems call F8 protein, human · ClinicalTrials.gg INT003681
- MeSH (NLM) C078147F8 protein, humanOne source NLM
- UNII (FDA) 839MOZ74GKANTIHEMOPHILIC FACTOR HUMANConfirmed FDA, NLM
- RxNorm 826070One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C078147 | F8 protein, human | One source NLM |
| UNII (FDA) | 839MOZ74GK | ANTIHEMOPHILIC FACTOR HUMAN | Confirmed FDA, NLM |
| RxNorm | 826070 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.